COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response- guideline (NG169)

Guideline aims to maximise safety of this population during the pandemic while protecting staff from infection. It brings together existing guidance/policies & advice from specialists with experience of treating patients with the specific health conditions covered by the guidance


National Institute for Health and Care Excellence